Author

Thelma M. Laot

Observed names: T. Laot, Thelma Laot, Thelma M Laot

Observed institutions: Research Institute for Tropical Medicine, Sanofi (France)

OpenAlex ID: A5044296660

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

2014 · Maria Rosario Capeding, Ngoc Huu Tran, et al. · The Lancet · 974

Dengue and Other Common Causes of Acute Febrile Illness in Asia: An Active Surveillance Study in Children

2013 · Maria Rosario Capeding, Mary Noreen Chua, et al. · PLoS neglected tropical diseases · 131

PDF

Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial

2020 · Guy de Bruyn, David L Gordon, et al. · The Lancet Infectious Diseases · 84

Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America

2018 · J.L. Arredondo-García, S.R. Hadinegoro, et al. · Clinical Microbiology and Infection · 66

Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial

2016 · Joshua Nealon, Anne-Frieda Taurel, et al. · PLoS neglected tropical diseases · 49

PDF

Rabies Post-Exposure Prophylaxis in the Philippines: Health Status of Patients Having Received Purified Equine F(ab')2 Fragment Rabies Immunoglobulin (Favirab)

2008 · Beatriz P. Quiambao, Hazel Z. DyTioco, et al. · PLoS neglected tropical diseases · 45

PDF

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

2021 · Rémi Forrat, Gustavo H Dayan, et al. · Clinical Infectious Diseases · 26

PDF

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

2023 · Gustavo H Dayan, Nadine Rouphael, et al. · The Lancet Respiratory Medicine · 25

PDF

Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period

2015 · Maria Rosario Capeding, Thelma M. Laot, et al. · Trials in Vaccinology · 19

Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV–Primed Children in the Philippines

2018 · Maria Rosario Capeding, Edison R Alberto, et al. · The Journal of Infectious Diseases · 17

PDF

First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers

2015 · Denis Crevat, Job D. Brion, et al. · The Pediatric Infectious Disease Journal · 15

Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults

2017 · Osamu Matsuoka, Dhaval M. Patel, et al. · Human Vaccines & Immunotherapeutics · 11

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

2025 · Leah I. B. Andrews, M. Elizabeth Halloran, et al. · JAMA Network Open · 6

PDF

Noninferiority Study of Purified Vero Rabies Vaccine—Serum Free in 3-dose and 2-dose Preexposure Prophylaxis Regimens in Comparison With Licensed Rabies Vaccines

2024 · Kulkanya Chokephaibulkit, Catherine Huoi, et al. · Clinical Infectious Diseases · 4

Integrated analysis of immunogenicity data from 11 dengue vaccine trials across 14 countries at risk for dengue

2016 · J. Menezes, C. Frago, et al. · International Journal of Infectious Diseases · 1

PDF

Antibody persistence and safety 3 years after CYD tetravalent dengue vaccination: follow-up results from a phase I trial in the Philippines

2012 · M.R.Z. Capeding, A. Wartel, et al. · International Journal of Infectious Diseases

PDF

Works count: 17

Citation count: 1,473

H-index: 11

I10-index: 12